Astellas Pharma Inc 2025 Integrated Report
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2025
Type: Integrated Report
Pages: 113
The report highlights Astellas' record FY2024 revenue and core operating profit, driven by Strategic Brands and continued R&D investment. It reports progress toward a 63% Scope 1+2 reduction and a 37.5% Scope 3 reduction by FY2030, alongside a net-zero emissions ambition for 2050. Sustainability disclosures cover materiality, access to health, environmental management, climate risk, resources, biodiversity and human rights. Important sustainability matters are deliberated by the Executive Committee and decided by the Board of Directors.
Services
From bulk PDFs to structured indicators and machine-readable documents.